H
Hiroshi Kitazawa
Researcher at Tohoku Pharmaceutical University
Publications - 21
Citations - 689
Hiroshi Kitazawa is an academic researcher from Tohoku Pharmaceutical University. The author has contributed to research in topics: Asthma & Natural killer T cell. The author has an hindex of 8, co-authored 19 publications receiving 549 citations. Previous affiliations of Hiroshi Kitazawa include Boston Children's Hospital & Tohoku University.
Papers
More filters
Journal ArticleDOI
Application of moisturizer to neonates prevents development of atopic dermatitis
Kenta Horimukai,Kumiko Morita,Masami Narita,Mai Kondo,Hiroshi Kitazawa,Makoto Nozaki,Yukiko Shigematsu,Kazue Yoshida,Hironori Niizeki,Kenichiro Motomura,Haruhiko Sago,Tetsuya Takimoto,Eisuke Inoue,Norio Kamemura,Hiroshi Kido,Junzo Hisatsune,Motoyuki Sugai,Hiroyuki Murota,Ichiro Katayama,Takashi Sasaki,Masayuki Amagai,Hideaki Morita,Akio Matsuda,Kenji Matsumoto,Hirohisa Saito,Yukihiro Ohya +25 more
TL;DR: Daily application of moisturizer during the first 32 weeks of life reduces the risk of AD/eczema in infants and allergic sensitization during this time period is associated with the presence of eczematous skin but not with moisturizer use.
Journal ArticleDOI
Platelets constitutively express IL-33 protein and modulate eosinophilic airway inflammation.
Tomohiro Takeda,Hirotoshi Unno,Hideaki Morita,Kyoko Futamura,Maiko Emi-Sugie,Ken Arae,Tetsuo Shoda,Naoko Okada,Arisa Igarashi,Eisuke Inoue,Hiroshi Kitazawa,Susumu Nakae,Hirohisa Saito,Kenji Matsumoto,Akio Matsuda +14 more
TL;DR: The novel findings suggest that platelets might be important cellular sources of IL- 33 protein in vivo and that platelet-derived IL-33 might play a role in airway inflammation, and might become an attractive novel therapeutic target for asthma and probably allergic inflammation.
Journal ArticleDOI
Japanese guidelines for childhood asthma 2020
Hirokazu Arakawa,Yuichi Adachi,Motohiro Ebisawa,Takao Fujisawa,Motohiro Ebisaw,Akira Akasawa,Toshishige Inoue,Yukihiro Ohya,Makoto Kameda,Kazuyuki Kurihara,Naoki Shimojo,Yutaka Suehiro,Hiroyuki Mochizuki,Shigemi Yoshihara,Takashi Iwanaga,Haruo Kuroki,Masato Takase,Ikuyo Masuko,Kota Hirai,Koichi Yoshida,Yuzaburo Inoue,Mizuho Nagao,Yumiko Miyaji,Misa Iio,Yasunori Ito,Takumi Takizawa,Masaki Futamura,Junichiro Tezuka,Hironobu Fukuda,Yukinori Yoshida,Hajime Nishimoto,Tatsuki Fukuie,Sakura Sato,Yoshiyuki Yamada,Ikuo Okafuji,Kiwako Yamamoto-Hanada,Mari Sasaki,Yuya Tanaka,Yoichi Nakajima,Atsushi Isozaki,Eisuke Inage,Hisako Yagi,Mayu Shimizu,Kenichi Akashi,Norio Kawamoto,Tetsuharu Manabe,Hiroki Murai,Yuri Takaoka,Taro Miura,Yukiko Hiraguchi,Takeshi Sugiyama,Mayumi Sugimoto,Shuichi Suzuki,Osamu Natsume,Hiroshi Kitazawa,Akiko Yamaide,Takuya Wada,Sankei Nishima +57 more
TL;DR: The Japanese Guideline for Childhood Asthma (JGCA) 2020 is a translation of the Japanese Pediatric Guideline (JPGL) 2017 into English, which makes recommendations for best practices in the management of childhood asthma, including management of acute exacerbations and non-pharmacological and pharmacological management.
Journal ArticleDOI
Interstitial Lung Disease in Childhood: Clinical and Genetic Aspects
Hiroshi Kitazawa,Shigeo Kure +1 more
TL;DR: The purpose of this review is to give an overview of the clinical and genetic aspects of ILD in children and to adopt new classification criteria based on the etiology to better understand the disease.
Journal ArticleDOI
Safety profile and immunological response of dual sublingual immunotherapy with house dust mite tablet and Japanese cedar pollen tablet
Minoru Gotoh,Kimihiro Okubo,Atsushi Yuta,Yukiko Ogawa,Hitoshi Nagakura,Shigehiro Ueyama,Tomoyo Ueyama,Kayoko Kawashima,Masashi Yamamoto,Shigeharu Fujieda,Masafumi Sakashita,Hirokazu Sakamoto,Naruhito Iwasaki,Eri Mori,Tomonori Endo,Nobuo Ohta,Hiroshi Kitazawa,Mitsuhiro Okano,Mikiya Asako,Masami Takada,Tetsuya Terada,Yuko Inaka,Syuji Yonekura,Tomokazu Matsuoka,Shinya Kaneko,Hiroki Hata,Nagisa Hijikata,Hisataka Tanaka,Keisuke Masuyama,Yoshitaka Okamoto +29 more
TL;DR: Dual therapy with both SLIT tablets administered within 5 min after 4 weeks of monotherapy with HDM or JCP tablet was well tolerated and induced the expected immunological responses.